331 related articles for article (PubMed ID: 37455222)
1. Blood has never been thicker: Cell-free DNA fragmentomics in the liquid biopsy toolbox of B-cell lymphomas.
Meriranta L; Pitkänen E; Leppä S
Semin Hematol; 2023 Jul; 60(3):132-141. PubMed ID: 37455222
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy in lymphoma: Molecular methods and clinical applications.
Cirillo M; Craig AFM; Borchmann S; Kurtz DM
Cancer Treat Rev; 2020 Dec; 91():102106. PubMed ID: 33049623
[TBL] [Abstract][Full Text] [Related]
3. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
[TBL] [Abstract][Full Text] [Related]
4. Bridging biological cfDNA features and machine learning approaches.
Moser T; Kühberger S; Lazzeri I; Vlachos G; Heitzer E
Trends Genet; 2023 Apr; 39(4):285-307. PubMed ID: 36792446
[TBL] [Abstract][Full Text] [Related]
5. Liquid biopsy: current technology and clinical applications.
Nikanjam M; Kato S; Kurzrock R
J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
[TBL] [Abstract][Full Text] [Related]
6. Multidimensional fragmentomic profiling of cell-free DNA released from patient-derived organoids.
Kim J; Hong SP; Lee S; Lee W; Lee D; Kim R; Park YJ; Moon S; Park K; Cha B; Kim JI
Hum Genomics; 2023 Oct; 17(1):96. PubMed ID: 37898819
[TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
[TBL] [Abstract][Full Text] [Related]
8. Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12 139 Cancer Patients.
Huang RSP; Xiao J; Pavlick DC; Guo C; Yang L; Jin DX; Fendler B; Severson E; Killian JK; Hiemenz M; Duncan D; Lin DI; Dennis L; Aiyer A; Gjoerup O; Oxnard G; Venstrom J; Elvin J; Ramkissoon SH; Ross JS
Clin Chem; 2021 Nov; 67(11):1554-1566. PubMed ID: 34626187
[TBL] [Abstract][Full Text] [Related]
9. Potential of modern circulating cell-free DNA diagnostic tools for detection of specific tumour cells in clinical practice.
Gašperšič J; Videtič Paska A
Biochem Med (Zagreb); 2020 Oct; 30(3):030504. PubMed ID: 32774122
[TBL] [Abstract][Full Text] [Related]
10. cfDNA-Based NGS IG Analysis in Lymphoma.
Pott C; Kotrova M; Darzentas N; Brüggemann M; Khouja M;
Methods Mol Biol; 2022; 2453():101-117. PubMed ID: 35622323
[TBL] [Abstract][Full Text] [Related]
11. Characterization of fragment sizes, copy number aberrations and 4-mer end motifs in cell-free DNA of hepatocellular carcinoma for enhanced liquid biopsy-based cancer detection.
Jin C; Liu X; Zheng W; Su L; Liu Y; Guo X; Gu X; Li H; Xu B; Wang G; Yu J; Zhang Q; Bao D; Wan S; Xu F; Lai X; Liu J; Xing J
Mol Oncol; 2021 Sep; 15(9):2377-2389. PubMed ID: 34133846
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor DNA in liquid biopsy: Current diagnostic limitation.
Liu SC
World J Gastroenterol; 2024 Apr; 30(15):2175-2178. PubMed ID: 38681986
[TBL] [Abstract][Full Text] [Related]
13. Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine.
Kerachian MA; Poudineh A; Thiery JP
Crit Rev Oncol Hematol; 2019 Dec; 144():102827. PubMed ID: 31715326
[TBL] [Abstract][Full Text] [Related]
14. Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer.
Gianni C; Palleschi M; Merloni F; Di Menna G; Sirico M; Sarti S; Virga A; Ulivi P; Cecconetto L; Mariotti M; De Giorgi U
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430675
[TBL] [Abstract][Full Text] [Related]
15. Deep cfDNA fragment end profiling enables cancer detection.
Zhitnyuk YV; Koval AP; Alferov AA; Shtykova YA; Mamedov IZ; Kushlinskii NE; Chudakov DM; Shcherbo DS
Mol Cancer; 2022 Jan; 21(1):26. PubMed ID: 35062943
[No Abstract] [Full Text] [Related]
16. Ultrasensitive Detection of Circulating Tumor DNA in Lymphoma via Targeted Hybridization Capture and Deep Sequencing of Barcoded Libraries.
Alcaide M; Rushton C; Morin RD
Methods Mol Biol; 2019; 1956():383-435. PubMed ID: 30779047
[TBL] [Abstract][Full Text] [Related]
17. Predicting tumour content of liquid biopsies from cell-free DNA.
Cardner M; Marass F; Gedvilaite E; Yang JL; Tsui DWY; Beerenwinkel N
BMC Bioinformatics; 2023 Sep; 24(1):368. PubMed ID: 37777714
[TBL] [Abstract][Full Text] [Related]
18. Methods for Measuring ctDNA in Lymphomas.
Rossi D; Condoluci A; Spina V; Gaidano G
Methods Mol Biol; 2019; 1881():253-265. PubMed ID: 30350211
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
20. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology.
Ponti G; Manfredini M; Tomasi A
Crit Rev Oncol Hematol; 2019 Sep; 141():36-42. PubMed ID: 31212145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
